Sopharma AD (BUL:SFA)

Market Cap	961.57M
Revenue (ttm)	2.14B
Net Income (ttm)	77.85M
Shares Out	166.36M
EPS (ttm)	0.47
PE Ratio	12.30
Forward PE	n/a
Dividend	0.15 (2.60%)
Ex-Dividend Date	Nov 7, 2024

Volume	3,439
Average Volume	6,021
Open	5.74
Previous Close	5.78
Day's Range	5.68 - 5.78
52-Week Range	5.52 - 6.32
Beta	-0.25
RSI	52.61
Earnings Date	Mar 31, 2025

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices...

• Industry: Pharmaceutical Preparations
• Founded: 1933
• Employees: 5,599
• Stock Exchange: Bulgarian Stock Exchange
• Ticker Symbol: SFA

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.